4-aza-5α-androstan-3-one-17β-carboxylic acid (F9 Acid)
This is the intermediate of dutasteride. Dutasteride is a new 5 α It is a dual inhibitor of reductase, which can inhibit 5 α Reductase-1 can also inhibit 5 α Reductase-2. It reduced the concentration of DHT more than finasteride (94.7% vs 70.8%). Dutasteride to 5 α The inhibitory effect of Reductase-1 was 60 times that of finasteride. The incidence rate of prostate cancer was 50% lower than that of placebo group 27 months after taking the drug.
Dutasteride can inhibit both type I and type II 5 α Reductase, through this * dual inhibition mechanism, can reduce the volume of prostate quickly and continuously, improve the symptoms of lower urinary tract, reduce the risk of acute urinary retention and related prostate surgery, and make patients benefit from enduring, especially the majority of moderate and severe benign prostatic hyperplasia patients.
Treat moderate and severe symptoms of benign prostatic hyperplasia (BPH). For patients with moderate or severe symptoms of benign prostatic hyperplasia, * reduce the risk of acute urinary retention (AUR) and surgery.